Last updated on Tuesday, 16 July 2024

Lovelace Medical Center-Saint Joseph Square

Trial #TypeStudy StatusStatus DateTitle
ASCO TAPURAdvanced Solid TumorsOpen Active2023-03-09ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
SWOG S1706Breast NeoadjuvantOpen Active2023-09-08SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
S2010Breast OtherOpen Active2023-10-16SWOG S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
SWOG S1912CDBreast OtherOpen Active2023-06-12SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT)
NRG-GU009GU OtherOpen Active2023-09-12NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)
NRG-GU010GU Prostate NeoadjuvantOpen Active2024-07-01NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
NRG-GU012GU Renal Cell AdvancedOpen Active2023-10-18NRG Oncology NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-12Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
DCP-001SupportiveOpen Active2016-08-17DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********

Lovelace Radiation Oncology

Trial #TypeStudy StatusStatus DateTitle
CCTG MA.39Breast NeoadjuvantOpen Active2018-10-10CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2023-09-08SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
SWOG S1912CDBreast OtherOpen Active2023-06-12SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT)
NRG-GU009GU OtherOpen Active2023-09-12NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)
NRG-GU010GU Prostate NeoadjuvantOpen Active2024-07-01NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
NRG-GU012GU Renal Cell AdvancedOpen Active2023-10-26NRG Oncology NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Lovelace Respiratory Research Institute

Trial #TypeStudy StatusStatus DateTitle
LRRI #1054101Lung AncillaryOpen Active2001-03-01LRRI #1054101: Defining Lung Cancer Risk in Current and Former Cigarette Smokers: Risk Factors for Epigenetic Silencing of Lung Cancer Genes

Lovelace Women's Hospital

Trial #TypeStudy StatusStatus DateTitle
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
INST UNM CR1801Breast OtherOpen Active2018-09-04INST UNM CR1801: Assessment of Intraoperative Radiofrequency Spectroscopy For Improving Lumpectomy Outcomes with Respect to Re-excision Rates and Lumpectomy Size
SWOG S1912CDBreast OtherOpen Active2023-06-12SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT)

Memorial Medical Center

Trial #TypeStudy StatusStatus DateTitle
ASCO TAPURAdvanced Solid TumorsOpen Active2021-10-20ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
INST DAREBreast AdvancedOpen Active2021-08-10INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE)
CCTG MA.39Breast NeoadjuvantOpen Active2018-08-21CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2023-09-08SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
SWOG S1703Breast OtherOpen Active2020-04-28SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
SWOG S1912CDBreast OtherOpen Active2023-01-18SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT)
NRG-GI008GI Colorectal AdjuvantOpen Active2022-08-19NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Alliance A032001GU Ureter AdvancedOpen Active2023-02-20Alliance A032001 MAIN-CAV: Phase III Randomized Trial Of Maintenance Cabozantinib And Avelumab Vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy In Patients With Metastatic Urothelial Cancer
ECOG-ACRIN EA3202Head And Neck AdvancedOpen Active2023-12-05ECOG-ACRIN EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
ALLIANCE A211901Head And Neck OtherOpen Active2023-03-31ALLIANCE A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
SWOG S1803Hematology MyelomaOpen Active2024-02-29SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2020-05-18ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-26SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
DCP-001SupportiveOpen Active2017-05-24DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001ASupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001DSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********

New Mexico Oncology Hematology Consultants

Trial #TypeStudy StatusStatus DateTitle
CCTG MA.39Breast NeoadjuvantOpen Active2018-11-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
RTOG 1216Head And Neck AdvancedOpen Active2023-11-29Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-17Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-17SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)

Presbyterian Medical Group

Trial #TypeStudy StatusStatus DateTitle
S2010Breast OtherOpen Active2023-05-30SWOG S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
Alliance A191901Breast OtherOpen Active2024-04-01Alliance A191901: Optimizing Endocrine Therapy Through Motivational Interviewing And Text Interventions
ASCO TAPURAdvanced Solid TumorsOpen Active2021-10-20ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Alliance A011801Breast AdjuvantOpen Active2021-05-17Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
INST DAREBreast AdvancedOpen Active2021-12-06INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE)
SWOG S2007Breast AdvancedOpen Active2023-07-20SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases
NRG-GY026GYN Endometrial NeoadjuvantOpen Active2023-05-22NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
NRG-GU010GU Prostate NeoadjuvantOpen Active2024-06-25NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
NRG-GU009GU OtherOpen Active2022-10-05NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)
NRG-GI008GI Colorectal AdjuvantOpen Active2022-08-19NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
SWOG S1703Breast OtherOpen Active2020-03-02SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
DCP-001SupportiveOpen Active2023-01-04DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2023-12-01ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Presbyterian Rust Medical Center

Trial #TypeStudy StatusStatus DateTitle
SWOG S2007Breast AdvancedOpen Active2023-07-20SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases
INST DAREBreast AdvancedOpen Active2021-12-06INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE)
Alliance A011801Breast AdjuvantOpen Active2021-05-17Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
ASCO TAPURAdvanced Solid TumorsOpen Active2021-10-20ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
NRG-GU010GU Prostate NeoadjuvantOpen Active2024-06-25NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
NRG-GU009GU OtherOpen Active2022-10-05NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)
NRG-GI008GI Colorectal AdjuvantOpen Active2022-08-19NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
SWOG S1703Breast OtherOpen Active2020-03-02SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
S2010Breast OtherOpen Active2023-05-30SWOG S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
Alliance A191901Breast OtherOpen Active2024-04-25Alliance A191901: Optimizing Endocrine Therapy Through Motivational Interviewing And Text Interventions
DCP-001SupportiveOpen Active2023-01-04DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2023-12-01ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
NRG-GY026GYN Endometrial NeoadjuvantOpen Active2022-11-22NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Southwest Gynecologic Oncology Associates

Trial #TypeStudy StatusStatus DateTitle
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********

UNM - CRTC

Trial #TypeStudy StatusStatus DateTitle
NRG Oncology NRG-BN003Brain OtherOpen Active2017-10-20NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Alliance A071401Brain AdvancedOpen Active2022-01-14Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations
ECOG-ACRIN EAY191Advanced Solid TumorsOpen Active2023-08-21ECOG-ACRIN EAY191: Molecular Analysis for Combination Therapy Choice (ComboMATCH)
ASCO TAPURAdvanced Solid TumorsOpen Active2021-10-20ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
INST DAREBreast AdvancedOpen Active2021-08-09INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE)
INST UNM 2004Breast AdjuvantOpen Active2022-05-27INST UNM 2004: Patient Understanding of the Benefit of Adjuvant Endocrine Therapy in Breast Cancer
Alliance A011801Breast AdjuvantOpen Active2021-05-17Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
NRG-BR007Breast NeoadjuvantOpen Active2021-10-29NRG Oncology NRG-BR007: A Phase III Clinical Trial evaluating de-escalation of Breast Radiation for conservative treatment of Stage I, hormone sensitive, HER2-Negative, Oncotype recurrence score = 18 Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-09-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S2007Breast AdvancedOpen Active2021-09-20SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases
ECOG-ACRIN EA1151Breast OtherOpen Active2022-09-29ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST)
ECOG-ACRIN EA1151Breast OtherOpen Active2018-08-31ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST)
SWOG S1706Breast NeoadjuvantOpen Active2023-09-08SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
SWOG S1912CDBreast OtherOpen Active2023-01-18SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT)
SWOG S1703Breast OtherOpen Active2020-03-02SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
S2010Breast OtherOpen Active2023-05-30SWOG S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
INST UNM 1803EpidemiologicalOpen Active2018-06-26INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative
INST UNM 1521 - TCCPEpidemiologicalOpen Active2017-12-08INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
CIBMTR Protocol for a Research DatabaseEpidemiologicalOpen Active2020-11-10CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
CIBMTR Protocol for a Research DatabaseEpidemiologicalOpen Active2017-06-29CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
INST UNM 1809GI Colorectal PreventionOpen Active2018-12-27INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States
Alliance A022101GI Colorectal AdvancedOpen Active2023-07-11Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
NRG-GI008GI Colorectal AdjuvantOpen Active2022-08-18NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Alliance A022104GI OtherOpen Active2024-01-18Alliance A022104: The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-Free Survival in Patients with Locally Advanced Rectal Cancer
ECOG-ACRIN EA2197GI Gastric AdjuvantOpen Active2021-05-28ECOG-ACRIN EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
ECOG-ACRIN EA2192GI Pancreatic AdjuvantOpen Active2023-09-13ECOG-ACRIN EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Alliance A021806GI Pancreatic AdjuvantOpen Active2020-12-08Alliance A021806: A Phase III Trial Of Perioperative Versus Adjuvant Chemotherapy For Resectable Pancreatic Cancer
INST UNM 1603GI OtherOpen Active2016-11-30INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health
NRG-GU009GU OtherOpen Active2022-04-15NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)
EA8212GU OtherOpen Active2023-08-07ECOG-ACRIN EA8212: A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Nave High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
SWOG S2104GI Pancreatic AdjuvantOpen Active2022-03-21SWOG S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumor
NRG-GU010GU Prostate NeoadjuvantOpen Active2024-06-25NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
UNM 1805GU OtherOpen Active2019-01-08INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors
NRG-GU011GU OtherOpen Active2022-08-08NRG Oncology NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
NRG EAY191-N4GYN Endometrial AdvancedOpen Active2023-08-21NRG EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
NRG-GY025GYN Endometrial AdjuvantOpen Active2023-10-13NRG Oncology NRG-GY025: A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
GOG-3043GYN Cervical AdjuvantOpen Active2022-06-29GOG Foundation, Inc. GOG-3043: A Randomized Controlled Trial of Robotic Versus Open Radical Hysterectomy for Cervical Cancer (ROCC)
SWOG S1931GU RenalCell AdjuvantOpen Active2023-10-11SWOG S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
UNM 1509GYN OtherOpen Active2020-06-29INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NRG-GY026GYN Endometrial NeoadjuvantOpen Active2024-04-12NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
NRG-GY028GYN Endometrial AdvancedOpen Active2023-05-04NRG Oncology NRG-GY028: A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
ECOG-ACRIN EA3202Head And Neck AdvancedOpen Active2023-12-05ECOG-ACRIN EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
ECOG-ACRIN EA3191Head And Neck AdvancedOpen Active2023-06-13ECOG-ACRIN EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
ECOG-ACRIN EA3161Head And Neck AdvancedOpen Active2023-10-13ECOG-ACRIN EA3161: A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
ALLIANCE A211901Head And Neck OtherOpen Active2023-03-31ALLIANCE A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
RTOG 1216Head And Neck AdvancedOpen Active2023-11-29Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
NRG-HN009Head And Neck AdvancedOpen Active2022-03-21NRG-Oncology NRG-HN009: Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
INST 1310Head And Neck AdvancedOpen Active2015-02-25INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
INST UNM 1512Hematology Acute LeukemiaOpen Active2018-05-23INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS
EA9152Hematology Acute LeukemiaOpen Active2023-06-09ECOG-ACRIN EA9152: A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
SWOG S2114Hematology Lymphoma Non-HodgkinsOpen Active2024-04-09SWOG S2114: A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Pharm EZH-302Hematology Lymphoma Non-HodgkinsOpen Active2022-06-21Epizyme EZH-302: A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SWOG S1905Hematology Acute LeukemiaOpen Active2023-12-19SWOG S1905: A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T- Cell Lymphoblastic Lymphoma (T-LBL)
INST UNM 1903Hematology OtherOpen Active2021-06-25INST UNM 1903: Collection of Apheresed Leukocytes for Research and Cell Therapy Process Development
SWOG S1803Hematology MyelomaOpen Active2023-12-08SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
ECOG ACRIN EAA181Hematology MyelomaOpen Active2021-12-17ECOG ACRIN EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-14SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN EA5182Lung NSCLC AdvancedOpen Active2023-05-03ECOG-ACRIN EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG S2302Lung NSCLC AdvancedOpen Active2023-08-04SWOG S2302: Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
SWOG S1914Lung NSCLC AdvancedOpen Active2023-11-30SWOG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
SWOG S1900ELung NSCLC AdvancedOpen Active2024-04-25SWOG S1900E: A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
DCP-001SupportiveOpen Active2016-08-17DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
SWOG S2101Solid Tumors OtherOpen Active2024-02-14SWOG S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
Alliance A081801Lung SCLC AdjuvantOpen Active2022-03-15Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
SWOG S2205SupportiveOpen Active2023-09-26SWOG S2205: ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Included Peripheral Neuropathy
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********